Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting

Prostate cancer currently represents 19% of all new cancer diagnoses in American men [1]. Despite response rates exceeding 80% with androgen deprivation therapy, effects of hormonal manipulation are temporary, and most patients progress to metastatic castration-resistant prostate cancer (mCRCaP) within a median of 3 years of diagnosis [2].
Source: Urologic Oncology: Seminars and Original Investigations - Category: Urology & Nephrology Authors: Tags: Original article Source Type: research